Osteoporosis in Chronic Obstructive Pulmonary Disease

Tin, Sim Sai; Wiwanitkita, Viroj

doi:10.4103/0970-2113.152674

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It reduces inflammation in the airways but also increases the risk of pulmonary infection, and oropharynx fungal infection. [27][28][29] Therefore, our aim is to examine the level of serum PARC/CCL18 in COPD patients and in normal population and analyze the association between serum PARC/CCL18 and clinical symptoms, pulmonary function, blood cell classification and counting, therapy in COPD, comprehensively. To achieve this end, serum samples from COPD patients and healthy volunteers were collected.…”

Section: Introductionmentioning

confidence: 99%

PARC/CCL18 is Associated with Inflammation, Emphysema Severity and Application of Inhaled Corticosteroids in Hospitalized COPD Patients

Duan

Liang

Liu

et al. 2021

COPD

View full text Add to dashboard Cite

Background: Pulmonary and activation-regulated chemokine (PARC) also named CCchemokine ligand 18 (CCL18) is a lung-predominant inflammatory protein that is found in serum. The relationship of PARC/CCL18 with the chronic obstructive pulmonary disease (COPD) is not fully understood. The aim of the present study is to analyze the expression of PARC/CCL18 in COPD. Methods: Ninety-eight hospitalized COPD patients and 60 healthy volunteers from January 2019 to December 2019 were recruited in this retrospective study. Gender, age, height, weight, disease duration, smoking status, blood cell classification and count, length of hospital stay (LOS), symptom score, including COPD Assessment Test (CAT) score, modified British Medical Research Council (mMRC) score, lung function and therapy were recorded and serum PARC/CCL18 was analyzed by ELISA. The correlation between symptom score, blood cell classification and count, CRP, lung function parameters and serum levels of PARC/CCL18 and ROC curves of PARC/CCL18 levels and inhaled corticosteroids (ICS) were accessed. Results: It was found that serum PARC/CCL18 level in hospitalized COPD population was significantly higher than that in healthy people (p=0.003). COPD patients with emphysema had significantly higher serum level of PARC/CCL18 than those without emphysema (p=0.049). Total lung capacity (TLC) and residual volume (RV)/TLC had positive correlation with serum level of PARC/CCL18 (p=0.001, 0.020, respectively). Furthermore, serum PARC/CCL18 level was predictive for the application ICS (p=0.003) and related to C-reactive protein (p <0.0001) in hospitalized COPD patients. Conclusion: PARC/CCL18 is associated with the severity of inflammation and emphysema in COPD. Furthermore, PARC/CCL18 is a predictor of ICS application in the treatment of hospitalized COPD patients.

show abstract

Section: Introductionmentioning

confidence: 99%